Astria Therapeutics (ATXS) News Today $12.15 +0.17 (+1.42%) Closing price 04:00 PM EasternExtended Trading$12.13 -0.02 (-0.16%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Astria Therapeutics (ATXS) Gets a Buy from LifeSci Capital2 hours ago | theglobeandmail.comBrokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $27.14October 20 at 3:27 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Cut to Hold at HC WainwrightOctober 19 at 2:05 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Cut to "Hold" at Citizens JmpOctober 18 at 2:53 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Cut to Neutral at WedbushOctober 18 at 2:53 AM | americanbankingnews.comAstria Therapeutics' (ATXS) Market Perform Rating Reiterated at JMP SecuritiesOctober 18 at 2:53 AM | americanbankingnews.comAstria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria ...October 17 at 6:34 PM | tmcnet.comAstria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXSOctober 17 at 3:20 PM | businesswire.comHC Wainwright & Co. Downgrades Astria Therapeutics (ATXS)October 16, 2025 | msn.comAstria Therapeutics' (ATXS) "Neutral" Rating Reiterated at HC WainwrightOctober 16, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Lowered to Hold Rating by WedbushOctober 16, 2025 | marketbeat.comCitizens Jmp Downgrades Astria Therapeutics (NASDAQ:ATXS) to HoldOctober 16, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Rating Lowered by Jefferies Financial GroupOctober 16, 2025 | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Sees Strong Trading Volume - What's Next?October 15, 2025 | marketbeat.comAstria Therapeutics' (ATXS) Market Perform Rating Reaffirmed at JMP SecuritiesOctober 15, 2025 | marketbeat.comSHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of ShareholdersOctober 15, 2025 | globenewswire.comJefferies Downgrades Astria Therapeutics (ATXS)October 15, 2025 | msn.comBioCryst to buy Astria Therapeutics for $13 per share (update)October 15, 2025 | msn.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 15, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)October 14, 2025 | prnewswire.comJefferies Financial Group Reiterates Hold Rating for Astria Therapeutics (NASDAQ:ATXS)October 14, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Gap Up - What's Next?October 14, 2025 | marketbeat.comShareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersOctober 14, 2025 | prnewswire.comATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to ShareholdersOctober 14, 2025 | businesswire.comBioCryst to buy Astria Therapeutics in $700 million dealOctober 14, 2025 | reuters.comWeiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS)October 9, 2025 | marketbeat.comAstria Therapeutics initiates ORBIT-EXPANSE trialOctober 8, 2025 | msn.comAstria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary AngioedemaOctober 8, 2025 | finance.yahoo.comAstria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEAOctober 3, 2025 | businesswire.comAstria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT TrialOctober 2, 2025 | finance.yahoo.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | businesswire.comAstria Therapeutics price target raised to $26 from $25 at Evercore ISIOctober 1, 2025 | msn.comGoldman Sachs Group Inc. Has $847,000 Holdings in Astria Therapeutics, Inc. $ATXSSeptember 24, 2025 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from AnalystsSeptember 20, 2025 | marketbeat.comHC Wainwright Boosts Astria Therapeutics (NASDAQ:ATXS) Price Target to $20.00September 18, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 18, 2025 | marketbeat.comAstria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and VenereologySeptember 17, 2025 | theglobeandmail.comAstria Therapeutics announces initial results from STAR-0310 trialSeptember 17, 2025 | msn.comAstria Therapeutics price target raised to $20 from $16 at H.C. WainwrightSeptember 17, 2025 | msn.comCubist Systematic Strategies LLC Buys 76,961 Shares of Astria Therapeutics, Inc. $ATXSSeptember 13, 2025 | marketbeat.comAstria Therapeutics, Inc. $ATXS Shares Sold by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.com103,517 Shares in Astria Therapeutics, Inc. $ATXS Acquired by Nuveen LLCSeptember 6, 2025 | marketbeat.comAstria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comADAR1 Capital Management LLC Has $3.43 Million Holdings in Astria Therapeutics, Inc. $ATXSSeptember 4, 2025 | marketbeat.comRedmile Group LLC Has $1.44 Million Position in Astria Therapeutics, Inc. $ATXSSeptember 4, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | businesswire.comAstria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025September 3, 2025 | finance.yahoo.comAstria Therapeutics, Inc. $ATXS Stake Lessened by Walleye Capital LLCSeptember 3, 2025 | marketbeat.com2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher UpsideSeptember 2, 2025 | finance.yahoo.comDriehaus Capital Management LLC Sells 133,574 Shares of Astria Therapeutics, Inc. $ATXSSeptember 2, 2025 | marketbeat.com Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXS Media Mentions By Week ATXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼-0.050.49▲Average Medical News Sentiment ATXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼304▲ATXS Articles Average Week Get the Latest News and Ratings for ATXS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Astria Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cogent Biosciences News Today Structure Therapeutics News Today Biohaven News Today Stoke Therapeutics News Today AbCellera Biologics News Today Immunocore News Today Vericel News Today Janux Therapeutics News Today Edgewise Therapeutics News Today Arcus Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
